Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

67%(2 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_2

20%

Ph phase_1

40%

Ph not_applicable

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

1(20.0%)

N/ANon-phased studies

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Other(1)

Detailed Status

Completed3

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (40.0%)

Phase 21 (20.0%)

N/A2 (40.0%)

Trials by Status

terminated120%

unknown120%

completed360%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_1

Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia

NCT02700048

unknownnot_applicable

Intranasal Insulin Improves Postoperative Neurocognitive Disorders in Elderly Patients

NCT05613491

completedphase_2

Clinical Trials (5)

Showing 5 of 5 trials

NCT02700048Phase 1

Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia

Terminated

NCT05613491Not Applicable

Intranasal Insulin Improves Postoperative Neurocognitive Disorders in Elderly Patients

Unknown

NCT02810392Phase 2

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

Completed

NCT02758691Phase 1

fMRI Study of Effects of Nasal Insulin on Memory

Completed

NCT03019237Not Applicable

Effect of Intranasal Anti-IgE Antibodies on IgE Production

Completed

All 5 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 5